Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1

Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1

US Patent 11865082 · Granted Jan 9, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibody molecules binding to CD3 and EGFRvIII2025
Bispecific antibody molecules binding to CD3 and EGFRvIII2025
Methods of treating cancer by administering tumor necrosis factor (TNF) family l2025
Methods of treating cancer by administering tumor necrosis factor (TNF) family l2025
Use of a cathepsin s inhibitor against the formation of anti-drug antibodies2025
Bispecific antibodies specific for PD1 and TIM32025
Bispecific antibodies specific for PD1 and TIM32025
Bispecific anti-human A-beta/anti-human transferrin receptor antibodies2025
Methods to determine antibody activity in tumor samples2025
Trispecific antibodies specific for HER2 and a blood brain barrier receptor and 2025
Antigen binding receptors specific for mutated Fc domains2025
Anti-FAP antibodies and methods of use2025